argenx (NASDAQ:ARGX) Given Outperform Rating at William Blair

William Blair reiterated their outperform rating on shares of argenx (NASDAQ:ARGX) in a research report report published on Friday,RTT News reports.

Several other analysts have also recently weighed in on ARGX. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and upped their price objective for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. Finally, Oppenheimer reiterated an “outperform” rating and set a $675.00 target price (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Stock Down 0.0 %

NASDAQ ARGX opened at $624.67 on Friday. The stock has a market cap of $37.96 billion, a P/E ratio of -709.85 and a beta of 0.58. The company’s 50-day simple moving average is $642.61 and its 200 day simple moving average is $589.72. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts anticipate that argenx will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenx

Hedge funds have recently bought and sold shares of the company. GeoWealth Management LLC raised its holdings in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares during the period. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter worth $37,000. Global Retirement Partners LLC increased its position in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd bought a new stake in shares of argenx during the fourth quarter worth $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenx during the fourth quarter worth $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.